Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rocket Companies Inc. Class A Common Stock (RKT) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

Rocket Companies Inc. Class A Common StockTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Rocket Companies Inc. Class A Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? Rocket Companies Inc. Class A Common Stock trades at $10.54 (market cap $30.67B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Rocket Companies Inc. Class A Common Stock is far larger — about 17× Vir Biotechnology Inc. Common Stock's market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, Rocket Companies Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rocket Companies Inc. Class A Common Stock for 0 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

RKTVIR
Market Cap
$30.67B$1.80B
Volume
41,104,1431,782,836
Sector
FinancialsHealth
52-Week High
$23.44$11.78
52-Week Low
$10.53$5.12
Typical Hold Time
0 Days0 Days
Enterprise Value
$60.66B$1.36B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rocket Companies Inc. Class A Common Stock

Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.

Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RKT
100% Buy0% Sell
Avg holding period · 0 Days
VIR
51% Buy49% Sell
Avg holding period · 0 Days

About Rocket Companies Inc. Class A Common Stock

Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.

Read more on RKT →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →